New Observer-Reported Outcomes To Measure Treatment Satisfaction, Compliance, Palatability, and Gi Symptoms for Patients Needing Iron-Chelation Therapy

Value Health. 2014 Nov;17(7):A534-5. doi: 10.1016/j.jval.2014.08.1706. Epub 2014 Oct 26.

Authors

K Lasch¹, E G Horodniceanu², J A Carter², H Dhatt², V Bal³, I Côté³, N Constantinovici⁴, R M Herranz⁴, I Malet⁴

Affiliations

¹ Pharmerit International, Cambridge, MA, USA.
² Pharmerit International, Bethesda, MD, USA.
³ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
⁴ Novartis Pharma AG, Basel, Switzerland.

PMID: 27201705
DOI: 10.1016/j.jval.2014.08.1706

No abstract available